Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00006
|
|||||
| Drug Name |
Moexipril
|
|||||
| Synonyms |
(3S)-2-(N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl)-6,7-bis(methyloxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid; Moexipril (INN); Moexipril [INN:BAN]; Moexiprilum; Moexiprilum [INN-Latin]; Perdix (TN); Uniretic; Univasc (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | High blood pressure [ICD11: BA00] | Approved | [1] | |||
| Therapeutic Class |
Antihypertensive Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C27H34N2O7
|
|||||
| Canonical SMILES |
CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CC3=CC(=C(C=C3CC2C(=O)O)OC)OC
|
|||||
| InChI |
InChI=1S/C27H34N2O7/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32)/t17-,21-,22-/m0/s1
|
|||||
| InChIKey |
UWWDHYUMIORJTA-HSQYWUDLSA-N
|
|||||
| CAS Number |
CAS 103775-10-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 498.6 | Topological Polar Surface Area | 114 | ||
| Heavy Atom Count | 36 | Rotatable Bond Count | 12 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 8 | |||
| XLogP |
1.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10224695
, 103339306
, 103831006
, 103984203
, 104404350
, 117576966
, 126683035
, 129432080
, 134222210
, 134337877
, 135049415
, 135153605
, 137003828
, 141323944
, 143493279
, 14884255
, 14933223
, 151982736
, 152164600
, 152238590
, 160964036
, 162178212
, 164786738
, 172914179
, 175266162
, 178103185
, 179149500
, 184545955
, 223440353
, 223653409
, 224369399
, 226420555
, 252390154
, 44422239
, 46508441
, 48416289
, 50077632
, 51009191
, 7980014
, 85789110
, 93166165
, 96024913
, 9906
|
|||||
| ChEBI ID |
ChEBI:6960
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | PEPT1 | Transporter Info | Peptide transporter 1 | Substrate | [2] | |
| PEPT2 | Transporter Info | Peptide transporter 2 | Substrate | [2] | ||
| References | ||||||
| 1 | Moexipril was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.